BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20071014)

  • 1. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
    Drenberg CD; Saunders BO; Wilbanks GD; Chen R; Nicosia RF; Kruk PA; Nicosia SV
    Gynecol Oncol; 2010 Apr; 117(1):117-24. PubMed ID: 20071014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
    Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The diagnostic and prognostic values of assay of serum vascular endothelial growth factor in epithelial ovarian cancer].
    Tan X; Shen K; Liu D; Xu X; Lang J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Aug; 22(4):352-5. PubMed ID: 12903449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.
    Chen CA; Cheng WF; Lee CN; Chen TM; Kung CC; Hsieh FJ; Hsieh CY
    Gynecol Oncol; 1999 Aug; 74(2):235-40. PubMed ID: 10419737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
    Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
    Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum endostatin levels in patients with epithelial ovarian cancer.
    Hata K; Dhar DK; Kanasaki H; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Nagasue N; Miyazaki K
    Anticancer Res; 2003; 23(2C):1907-12. PubMed ID: 12820477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
    Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
    Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
    Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV
    Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
    Hazelton D; Nicosia RF; Nicosia SV
    Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
    Feldman AL; Tamarkin L; Paciotti GF; Simpson BW; Linehan WM; Yang JC; Fogler WE; Turner EM; Alexander HR; Libutti SK
    Clin Cancer Res; 2000 Dec; 6(12):4628-34. PubMed ID: 11156212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary levels of Bcl-2 are elevated in ovarian cancer patients.
    Anderson NS; Bermudez Y; Badgwell D; Chen R; Nicosia SV; Bast RC; Kruk PA
    Gynecol Oncol; 2009 Jan; 112(1):60-7. PubMed ID: 19007973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
    Peng XP; Li JD; Li MD; Ye XM; Yan WC
    Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of endostatin, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with acute myocardial infarction undergoing early reperfusion therapy.
    Seko Y; Fukuda S; Nagai R
    Clin Sci (Lond); 2004 May; 106(5):439-42. PubMed ID: 14965340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
    Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
    Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.